CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血液系统恶性肿瘤中 CAR-T 细胞治疗：肿瘤微环境与生物标志物对疗效和毒性的影响
英文原题：CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity.
查看英文原题
CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法开启了癌症治疗的新纪元，并已使既往难治的复发/难治性血液系统恶性肿瘤患者获得显著疗效。然而，优化疗效并降低毒性风险仍是重大挑战，限制了该疗法的成功。肿瘤微环境（TME）会影响CAR-T 细胞治疗效果及毒性风险。越来越多的研究也发现了可预测疗效和毒性风险的各类生物标志物。本文综述目前已知的TME和相关生物标志物，并讨论建立评分系统的作用，以进一步优化CAR-T 临床应用，为个体制定安全有效的精准治疗方案。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy has ushered in a new era in cancer treatment. Remarkable outcomes have been demonstrated in patients with previously untreatable relapsed/refractory hematological malignancies.
However, optimizing efficacy and reducing the risk of toxicities have posed major challenges, limiting the success of this therapy. The tumor microenvironment (TME) plays an important role in CAR T cell therapy's effectiveness and the risk of toxicities. Increasing research studies have also identified various biomarkers that can predict its effectiveness and risk of toxicities.
In this review, we discuss the various aspects of the TME and biomarkers that have been implicated thus far and discuss the role of creating scoring systems that can aid in further refining clinical applications of CAR T cell therapy and establishing a safe and efficacious personalised medicine for individuals.
论文信息
- 作者
- Tan JY、Low MH、Chen Y、Lim FLWI
- 单位
- Department of Hematology, Singapore General Hospital Singapore, Outram Road, Singapore 169608, Singapore.Singapore
- 文献类型
- 综述
- 期刊
- International journal of molecular sciences2022 Jun 22
- 原文标识
- PubMed 35805933 · DOI 10.3390/ijms23136931
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →